New Alzheimer’s target
Enlarge image


New Alzheimer’s target

04.12.2012 - Scientists from VIB and KU Leuven have discovered a new target that could lay the foundations for a new approach to treat Alzheimer’s disease.

The research team, headed by Bart de Strooper from VIB, found that β-arrestin 2 blocks the plaque-form enzyme γ-secretase through interaction with the G protein–coupled receptors GPR3 and β2 -adrenergic receptor (Nature Medicine). Furthermore, they demonstrated that β-arrestin 2 was overexpressed in two independent cohorts of Alzheimer patients. Overexpression of the protein led to an increase in sticky amyloid-β (Aβ) peptides, called Aβ40 and Aβ42, which form the amyloid plaques that are associated with neurodegeneration. In contrast, genetic silencing of Arrb2, which encodes β-arrestin 2, reduced generation of Aβ in cell cultures and in knock-out mice for the Alzheimer regulator. The effect was mediated by direct binding to the Aph-1a subunit of the γ-secretase complex, which enzymatically generates the sticky Aβ peptides. Thus the scientists believe that inhibitors of β-arrestin 2 could block the generation of Aβ40 and Aβ42, in early stages of Alzheimer’s when no symptoms have yet emerged.

Currently there is no cure for the neurodegenerative disease. Many candidate drugs that target the γ-secretase complex fail because they also target proteins essential to life. The discovery from Leuven could form a target for a treatment against Alzheimer’s disease with fewer side effects and that suppresses the very first symptoms of the disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. This study thus provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer’s disease.



24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


04.11.2015 What biotech stock market slump? Despite all odds, 2015 is set to become a new record year for the European public biotech sector, according to a BIOCOM-study presented at BIO Europe in Munich.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • SERODUS (N)2.67 NOK9.43%
  • VERONA PHARMA (UK)3.03 GBP8.21%


  • BIOFRONTERA (D)1.70 EUR-12.82%
  • DIAMYD MEDICAL -B- (S)9.30 SEK-11.43%
  • IMMUPHARMA (UK)23.00 GBP-6.12%


  • PLETHORA (UK)5.50 GBP83.3%
  • PROTHENA PLC (IE)70.04 USD42.0%
  • IMMUNICUM AB (S)43.10 SEK33.4%


  • EPIGENOMICS (D)1.85 EUR-61.4%
  • EVOCUTIS (UK)0.10 GBP-28.6%


  • KARO BIO (S)38.40 SEK5233.3%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.40 EUR269.7%


  • BIOTEST (D)15.25 EUR-80.8%
  • NEOVACS (F)0.72 EUR-78.1%

No liability assumed, Date: 24.11.2015